Target species
Turkeys.
Indications for use
For the active immunisation of turkeys to reduce mortality caused by Erysipelothrix rhusiopathiae.
Onset of immunity: 6 weeks post second vaccination.
Duration of immunity: 23 weeks post second vaccination.
Contraindications
None.
Special warnings for each target species
Vaccinate healthy animals only.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Special precautions for use
Not applicable.
Operator warnings
Not applicable.
Adverse reactions
Turkeys:
None known.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy or lactation
Do not use in birds in lay and within 2 weeks before the start of the laying period.
Interactions
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.
Amounts to be administered and administration route
Dose: 0.5 ml.
Administration: Subcutaneous use.
Turkeys are to be vaccinated twice. Subcutaneous injection of 0.5 ml (one dose) of vaccine can take place from six weeks of age onwards. Vaccination is repeated after 4 weeks. The second vaccination for breeder turkeys must be given not later than two weeks before the onset of the laying period.
Before using the vaccine allow it to reach room temperature (15 °C - 25 °C) and shake before and intermittently during use. Use sterile syringes and needles. Avoid introduction of contamination by multiple broaching.
Overdose
No particular clinical signs after administration of a two-fold overdose.
Withdrawal periods
Zero days.